T2 Biosystems Reminds Stockholders to Vote at the Upcoming Annual Meeting
May 25 2021 - 4:46PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today reminded stockholders
to vote at the upcoming 2021 Annual Meeting of Stockholders to be
held on June 25, 2021. The T2 Biosystems Board of Directors
unanimously supports each stockholder proposal on the proxy and
encourages all stockholders to vote for these proposals.
The Company’s President and CEO, John Sperzel, has released a
statement communicating to stockholders the importance of the
proposals and their potential impact on the Company. The video
statement can be found on the Investor Relations section of the
Company’s website at investors.t2biosystems.com.
T2 Biosystems, Inc. will be holding its Annual Meeting virtually
on June 25, 2021 at 9:00 a.m. Eastern Time
at www.virtualshareholdermeeting.com/TTOO2021. T2 Biosystems’
stockholders of record as of April 28, 2021 are entitled to vote at
the Annual Meeting.
T2 Biosystems’ definitive proxy materials, 2020 Annual Report to
Stockholders and other relevant information can be found
at www.sec.gov.
If you have any questions about how to vote your shares, or need
additional assistance, please contact MacKenzie Partners at
1-800-322-2885.
About T2 BiosystemsT2 Biosystems, a leader
in the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Cauris™ Panel, and T2Lyme™
Panel, as well as additional products for the detection of
bacterial and fungal pathogens and associated antimicrobial
resistance markers, and biothreat pathogens.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, without limitation, statements regarding the stockholder
proposals and their potential impact, as well as statements that
include the words “expect,” “intend,” “plan”, “believe”, “project”,
“forecast”, “estimate,” “may,” “should,” “anticipate,” and similar
statements of a future or forward looking nature. These
forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments,
contracts or products; (b) successfully execute strategic
priorities; (c) bring products to market; (d) expand product usage
or adoption; (e) obtain customer testimonials; (f) accurately
predict growth assumptions; (g) realize anticipated revenues; (h)
incur expected levels of operating expenses; or (i) increase the
number of high-risk patients at customer facilities; (ii) failure
of early data to predict eventual outcomes; (iii) failure to
make or obtain anticipated FDA filings or clearances within
expected time frames or at all; or (iv) the factors discussed under
Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2020, filed with the U.S.
Securities and Exchange Commission, or SEC, on March 31, 2021, and
other filings the Company makes with the SEC from time to
time. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While the Company may elect to
update such forward-looking statements at some point in the future,
unless required by law, it disclaims any obligation to do so, even
if subsequent events cause its views to change. Thus, no one should
assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements
should not be relied upon as representing the Company's views as of
any date subsequent to the date of this press release.
Important Information
The Company, its directors, director nominees and certain of its
executive officers are participants in the solicitation of proxies
from stockholders in respect of the Annual Meeting. The Company has
filed a definitive proxy statement and associated proxy card in
connection with the solicitation of proxies for the Annual Meeting
with the SEC. Details concerning the nominees of the Company’s
board of directors for election at the Annual Meeting are set forth
in the definitive proxy statement. BEFORE MAKING ANY VOTING
DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL
RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING
THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS
THERETO, AS THEY CONTAIN IMPORTANT INFORMATION. Information
regarding the identity of the Company’s participants and their
respective interests in the matters to be voted on at the Annual
Meeting, by security holdings or otherwise, are set forth in the
definitive proxy statement and other documents filed with the SEC
in connection with the Annual Meeting. Investors and stockholders
can obtain a copy of the definitive proxy statement and other
documents filed by the Company free of charge from the SEC’s
website at www.sec.gov. The Company’s stockholders can also obtain,
without charge, a copy of the definitive proxy statement and other
relevant filed documents from the “SEC Filings” section of the
Company’s website at www.t2biosystems.com.
Media Contact:Gina Kent, Vault
Communicationsgkent@vaultcommunications.com 610-455-2763
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Aug 2024 to Sep 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Sep 2023 to Sep 2024